PROMUS Element™ Plus H7493911428350Recalls & reported problems
Boston Scientific Corporation · Everolimus-Eluting Platinum Chromium Coronary Stent System · Class 3
All models of PROMUS Element Plus (44)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08714729808046), received between Jan 5, 2017 and Jan 5, 2017 — classified as 1 injury.
The most frequently reported specific device problem is “Occlusion Within Device” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Occlusion Within Device1
Patient problems
- Angina1
- Reocclusion1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryJan 5, 2017Occlusion Within Device; Occlusion Within Device
SAME CASE AS MDR ID: 2134265-2016-12409 (B)(6) STUDY. IT WAS REPORTED THAT IN STENT RESTENOSIS AND ANGINA OCCURRED. IN (B)(6) 2012, THE PATIENT PRESENTED DUE TO UNSTABLE ANGINA AND WAS REFERRED FOR CARDIAC CATHETERIZATION. SUBSEQUENTLY, INDEX PROCEDURE WAS PERFORMED. TARGET LESION # 1 WAS AN OSTIAL LESION LOCATED IN THE PROXIMAL PORTION OF SAPHENOUS VEIN GRAFT (SVG) TO OBTUSE MARGINAL (OM1) WITH 90% STENOSIS AND WAS 24 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3.5 MM. TARGET LESION # 1 WAS TREATED WITH DIRECT STENT PLACEMENT USING A 3.50 X 28 MM PROMUS ELEMENT¿ PLUS STENT, WITH 10% RESIDUAL STENOSIS. TARGET LESION # 2 WAS A DE NOVO LESION LOCATED IN THE DISTAL LEFT CIRCUMFLEX (LCX) WITH 90% STENOSIS AND WAS 8 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.25 MM. TARGET LESION # 2 WAS TREATED WITH PRE-DILATATION AND PLACEMENT OF A 2.25 MM X 12 MM PROMUS ELEMENT¿ PLUS STENT. FOLLOWING POST-DILATATION, RESIDUAL STENOSIS WAS 0%. TARGET LESION # 3 WAS A DE NOVO LESION LOCATED IN THE LEFT MAIN CORONARY ARTERY (LMCA) WITH 95% STENOSIS AND WAS 24 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.75 MM. TARGET LESION # 3 WAS TREATED WITH PRE-DILATATION AND PLACEMENT OF A 2.75 X 28 MM PROMUS EL
Patient problems: Angina; Reocclusion
MAUDE report 6226044 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page